MTIM
MRNA icon

Marathon Trading Investment Management’s Moderna MRNA Stock Holding History

Marathon Trading Investment Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-33,500
Closed -$1.7M – 314
2026
Q1 		$1.7M Buy
+33,500
New +$1.56M 0.05% 68
2025
Q2 		– Sell
-3,300
Closed -$93.6K – 341
2025
Q1 		$93.6K Buy
3,300
+1,800
+120% +$63.9K 0.01% 274
2024
Q4 		$62.4K Sell
1,500
-3,400
-69% -$163K ﹤0.01% 263
2024
Q3 		$327K Sell
4,900
-1,200
-20% -$110K 0.03% 174
2024
Q2 		$724K Sell
6,100
-2,600
-30% -$329K 0.05% 118
2024
Q1 		$927K Buy
8,700
+7,200
+480% +$726K 0.07% 117
2023
Q4 		$149K Sell
1,500
-100
-6% -$8.41K 0.01% 284
2023
Q3 		$165K Sell
1,600
-1,100
-41% -$123K 0.01% 234
2023
Q2 		$328K Buy
+2,700
New +$360K 0.03% 153
2023
Q1 		– Sell
-800
Closed -$144K – 308
2022
Q4 		$144K Sell
800
-2,100
-72% -$343K 0.02% 197
2022
Q3 		$343K Buy
+2,900
New +$440K 0.03% 181
2020
Q4 		– Sell
-5,800
Closed -$410K – 377
2020
Q3 		$410K Buy
+5,800
New +$404K 0.03% 207

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Marathon Trading Investment Management's MRNA Position: Q2 2026 in Review

Marathon Trading Investment Management sold out of Moderna (MRNA) in Q2 2026, closing a stake of 203 shares — an estimated $10.3K sold.

Marathon Trading Investment Management first reported a position in MRNA in Q4 2020 and held it in 11 quarters. The position peaked at $2.84M in Q4 2023. 784 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Marathon Trading Investment Management reported no remaining Moderna position as of Q2 2026 after selling out during the quarter.
  • Marathon Trading Investment Management sold 203 Moderna shares in Q2 2026, an estimated $10.3K.
  • Marathon Trading Investment Management first reported a position in Moderna in Q4 2020 and held it in 11 quarters.
  • Marathon Trading Investment Management's Moderna position peaked at $2.84M in Q4 2023.
  • 784 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Marathon Trading Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.